Last Price$71.4(0.3%)
Market Cap$43.4B
LTM Diluted EPS
$6.9
YoY Growth
+196.2%
3Y CAGR
+43.4%
5Y CAGR
+41.8%
Stock quality & Intrinsic value
6/10
24.2% overvalued
Edwards Lifesciences Corporation Diluted EPS
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS | $0.1 | $0.2 | $0.2 | $0.2 | $0.3 | $0.3 | $0.3 | $0.4 | $0.6 | $1.3 | $0.8 | $0.9 | $1.0 | $1.1 | $1.6 | $1.3 | $2.4 | $2.4 | $2.3 | $7.0 |
Overvalued or undervalued?
Check the intrinsic value for EW
and see if it's the right time to invest.
Edwards Lifesciences Corporation (EW) Diluted EPS comparison analysis
General
LTM Diluted EPS
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Edwards Lifesciences CorporationEW
$6.9
196.2%
43.4%
41.8%
Median Peer Set
$4.0
(4.7%)
15.9%
0.4%
Stryker CorporationSYK
$7.8
(5.8%)
14.2%
7.2%
Abbott LaboratoriesABT
$7.7
135.3%
24.8%
29.9%
Insulet CorporationPODD
$5.8
97.9%
188.8%
100.0%
Align Technology, Inc.ALGN
$5.6
(3.6%)
(16.7%)
0.3%
STERIS plcSTE
$4.7
(17.6%)
17.6%
0.5%
Zimmer Biomet Holdings, Inc.ZBH
$3.3
(33.5%)
19.6%
(9.9%)
DexCom, Inc.DXCM
$1.4
8.4%
42.6%
38.7%
Boston Scientific CorporationBSX
$0.9
(18.7%)
6.2%
(23.5%)
Medtronic plcMDT
$0.5
(84.4%)
(48.7%)
(34.1%)
Koninklijke Philips N.V.PHG
($0.9)
46.6%
N/A
N/A
EW key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 997.9 7.1% | 1,037.0 3.9% | 1,091.1 5.2% | 1,237.7 13.4% | 1,321.4 6.8% | 1,447.0 9.5% | 1,678.6 16.0% | 1,899.6 13.2% | 2,045.5 7.7% | 2,322.9 13.6% | 2,493.7 7.4% | 2,963.7 18.8% | 3,435.3 15.9% | 3,722.8 8.4% | 4,348.0 16.8% | 4,386.3 0.9% | 5,232.5 19.3% | 5,382.4 2.9% | 6,004.8 11.6% | 5,439.5 (9.4%) |
| Cost of Goods Sold (COGS) | 374.6 | 373.6 | 378.2 | 419.6 | 399.1 | 408.3 | 489.8 | 494.6 | 522.4 | 625.6 | 617.2 | 797.4 | 875.3 | 939.4 | 1,114.4 | 1,080.6 | 1,248.9 | 1,080.4 | 1,379.8 | 1,117.5 |
% margin | 623.3 62.5% | 663.4 64.0% | 712.9 65.3% | 818.1 66.1% | 922.3 69.8% | 1,038.7 71.8% | 1,188.8 70.8% | 1,405.0 74.0% | 1,523.1 74.5% | 1,697.3 73.1% | 1,876.5 75.2% | 2,166.3 73.1% | 2,560.0 74.5% | 2,783.4 74.8% | 3,233.6 74.4% | 3,305.7 75.4% | 3,983.6 76.1% | 4,302.0 79.9% | 4,625.0 77.0% | 4,322.0 79.5% |
| Operating Expenses | 447.7 | 490.2 | 540.3 | 643.8 | 684.3 | 754.4 | 888.7 | 996.6 | 1,068.6 | 1,204.5 | 1,233.8 | 1,348.0 | 1,537.3 | 1,710.7 | 1,994.9 | 1,989.1 | 2,396.8 | 2,512.8 | 3,090.9 | 2,842.2 |
| Research & Development Expenses (R&D) | 99.0 | 114.2 | 122.3 | 139.2 | 175.5 | 204.4 | 246.3 | 291.3 | 323.0 | 346.5 | 383.1 | 443.3 | 552.6 | 622.2 | 752.7 | 760.7 | 903.1 | 945.2 | 1,071.8 | 1,053.0 |
| Selling, General & Administrative Expenses (SG&A) | 348.7 | 376.0 | 418.0 | 480.6 | 508.8 | 550.0 | 642.4 | 705.3 | 745.6 | 858.0 | 850.7 | 904.7 | 984.7 | 1,088.5 | 1,242.2 | 1,228.4 | 1,493.7 | 1,567.6 | 1,824.6 | 1,789.2 |
% margin | 175.6 17.6% | 173.2 16.7% | 172.6 15.8% | 198.3 16.0% | 238.0 18.0% | 284.3 19.6% | 300.1 17.9% | 408.4 21.5% | 454.5 22.2% | 482.6 20.8% | 642.7 25.8% | 783.8 26.4% | 1,022.7 29.8% | 748.2 20.1% | 1,146.8 26.4% | 1,628.4 37.1% | 1,348.5 25.8% | 1,748.5 32.5% | 1,534.1 25.5% | (0.3) (0.0%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 6.1 | 1.6 | 0.9 | 3.4 | 0.4 | 4.6 | 6.4 | 7.9 | 10.8 | 20.3 | 32.0 | 11.5 | 23.4 | 17.4 | 35.5 | 67.2 | (120.3) |
| Interest Expense | 9.7 | 0.0 | 0.0 | 7.2 | 1.1 | 2.4 | 3.1 | 4.4 | 5.2 | 10.8 | 9.3 | 8.4 | 2.9 | 29.9 | 20.7 | 15.8 | 18.4 | 19.2 | 17.6 | 19.8 |
| Pre-tax Income | 116.7 | 172.3 | 149.8 | 164.4 | 304.4 | 268.2 | 283.6 | 391.1 | 515.3 | 1,144.0 | 622.4 | 737.9 | 1,034.9 | 761.4 | 1,166.5 | 916.7 | 1,702.0 | 1,767.4 | 1,598.1 | 1,548.1 |
% effective tax rate | 37.4 32.0% | 41.8 24.3% | 36.8 24.6% | 35.5 21.6% | 75.3 24.7% | 50.2 18.7% | 46.9 16.5% | 97.9 25.0% | 123.6 24.0% | 332.9 29.1% | 127.5 20.5% | 168.4 22.8% | 412.8 39.9% | 39.2 5.1% | 119.6 10.3% | 93.3 10.2% | 198.9 11.7% | 245.5 13.9% | 198.7 12.4% | 152.1 9.8% |
% margin | 79.3 7.9% | 130.5 12.6% | 113.0 10.4% | 128.9 10.4% | 229.1 17.3% | 218.0 15.1% | 236.7 14.1% | 293.2 15.4% | 391.7 19.1% | 811.1 34.9% | 494.9 19.8% | 569.5 19.2% | 622.1 18.1% | 722.2 19.4% | 1,046.9 24.1% | 823.4 18.8% | 1,503.1 28.7% | 1,521.9 28.3% | 1,402.4 23.4% | 4,174.6 76.7% |
| EPS | 0.11 | 0.19 | 0.16 | 0.19 | 0.34 | 0.32 | 0.35 | 0.43 | 0.59 | 1.27 | 0.77 | 0.89 | 0.98 | 1.15 | 1.68 | 1.32 | 2.41 | 2.46 | 2.31 | 6.98 |
| Diluted EPS | 0.11 | 0.18 | 0.16 | 0.18 | 0.33 | 0.31 | 0.33 | 0.41 | 0.57 | 1.25 | 0.75 | 0.87 | 0.96 | 1.13 | 1.64 | 1.30 | 2.38 | 2.44 | 2.30 | 6.97 |
% margin | 185.2 18.6% | 230.0 22.2% | 227.4 20.8% | 227.2 18.4% | 365.8 27.7% | 327.1 22.6% | 344.7 20.5% | 452.8 23.8% | 589.8 28.8% | 563.4 24.3% | 708.7 28.4% | 890.6 30.1% | 1,104.3 32.1% | 1,150.2 30.9% | 1,308.4 30.1% | 1,074.3 24.5% | 1,890.1 36.1% | 1,960.4 36.4% | 1,767.6 29.4% | (0.3) (0.0%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Edwards Lifesciences Corporation's Diluted EPS?
As of today, Edwards Lifesciences Corporation's last 12-month Diluted EPS is $6.9, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Edwards Lifesciences Corporation's Diluted EPS growth rate?
Over the last year, Edwards Lifesciences Corporation's Diluted EPS growth was 196.2%. The average annual Diluted EPS growth rates for Edwards Lifesciences Corporation have been 72.5% over the past three years, 41.8% over the past five years.
3) Is Edwards Lifesciences Corporation's Diluted EPS growth rate Good?
Over the last year, Edwards Lifesciences Corporation's Diluted EPS growth was 196.2%, which is higher than industry growth of (0.3%). It indicates that Edwards Lifesciences Corporation's Diluted EPS growth is Good.